



PATENT
Docket No. 265.00390101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Boldogh et al.)	Group Art Unit:	1656
)		
Serial No.:	10/691,330)	Examiner:	Chih Min Kam
Confirmation No.:	1384)		
)		
Filed:	October 22, 2003)		
)		
For:	USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND ANALOGS THEREOF AS INHIBITORS OF APOPTOSIS AND OTHER CELLULAR DAMAGE			

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Pursuant to MPEP § 609, the information cited in the present Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested. Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

It is believed that no fee is due, as this Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 13-4895.

Supplemental Information Disclosure Statement

Page 2 of 2

Applicant(s): Boldogh et al.

Serial No.: 10/691,330

Confirmation No.: 1384

Filed: October 22, 2003

For: USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND ANALOGS THEREOF AS
INHIBITORS OF APOPTOSIS AND OTHER CELLULAR DAMAGE

The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

CERTIFICATE UNDER 37 C.F.R. 1.10:

The undersigned hereby certifies that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated below and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

"Express Mail" mailing label number:

EV 201880111 US

Date of Deposit: April 25, 2007

By: Danielle Moritz

Name: Danielle Moritz

April 25, 2007
Date

Respectfully submitted

By

Mueiting, Raasch & Gebhardt, P.A.

P.O. Box 581415

Minneapolis, MN 55458-1415

Phone: (612)305-1220

Facsimile: (612)305-1228

Customer Number 26813

By: Nancy A. Johnson

Nancy A. Johnson

Reg. No. 47,266

Direct Dial (612)305-4723

**INFORMATION
DISCLOSURE
STATEMENT**

Atty. Docket No.: 265.00390101

Serial No.: 10/691,330

Applicant(s): Boldogh et al.

Confirmation No.: 1384

Application Filing Date: October 22, 2003

Group: 1656

Information Disclosure Statement mailed: April 25, 2007**U.S. PATENT DOCUMENTS**

Examiner Initial	Copy Enclosed	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		60/420,369		Stanton et al.			10/22/02

FOREIGN PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	X	WO 2004/081038		PCT				

OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)

Examiner Initial	Copy Enclosed	Document Description
	X	Bacsi et al., "Colostrinin decreases spontaneous and induced mutation frequencies at the hprt locus in Chinese hamster V79 cells," <i>Journal of Experimental Therapeutics and Oncology</i> , 2006;5:249-259.

EXAMINER**Date Considered**

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.